| Literature DB >> 22686856 |
Ramalingam Sasikala1, Kannan Thirumurthy, Perumal Mayavel, Ganesamoorthy Thirunarayanan.
Abstract
BACKGROUND: Green catalyst fly ash: H2SO4 was prepared by mixing fly ash and sulphuric acid. Microwave irradiations are applied for solid phase cyclization of 5-bromo-2-thienyl chalcones and phenyl hydrazine hydrate in the presence of fly ash: H2SO4 yields, 1-phenyl-3(5-bromothiophen-2-yl)-5-(substituted phenyl)-2-pyrazolines. These pyrazolines were characterized by their physical constants and spectral data. The antimicrobial activities of all synthesized pyrazolines have been studied.Entities:
Year: 2012 PMID: 22686856 PMCID: PMC3534571 DOI: 10.1186/2191-2858-2-20
Source DB: PubMed Journal: Org Med Chem Lett ISSN: 2191-2858
Analytical and mass spectral data of 1-phenyl-3(5-bromothiophen-2-yl)-5-(substituted phenyl)-2-pyrazolines
| 1 | H | C20H17BrN2 | 365 | 85 | 152-153 | 365[M+], 367[M+2], 287, 285, 221, 209, 142, 79, 77, 68, 65, 41, 28, 14 |
| 2 | 4-Br | C20H16Br2N2 | 444 | 83 | 148-150 | 444[M+], 446[M+2], 448[M+4], 365, 363, 229, 222, 201, 155, 142, 77, 68, 41, 28, 14. |
| 3 | 2-Cl | C20H17BrClN2 | 399 | 75 | 142-144 | 399[M+], 401[M+2], 403[M+4], 363, 321, 319, 287, 225, 209, 142, 111, 77, 68, 65, 41, 28, 35, 14 |
| 4 | 4-Cl | C20H17BrClN2 | 399 | 79 | 147-149 | 399[M+], 401[M+2], 403[M+4], 363, 321, 287, 225, 209, 142 77, 65, 41, 28, 14 |
| 5 | 3, 4-(OCH3)2 | C22H21BrN2O2 | 425 | 85 | 140-142 | 425[M+], 427[M+2], 393, 363, 347, 287, 251, 142, 134, 107, 95, 78, 65, 41, 28, 14 |
| 6 | 4-I | C20H17BrIN2 | 491 | 76 | 146-148 | 491[M+], 493[M+2], 495[M+4], 412, 363, 347, 287, 269, 229, 203, 142, 126, 77, 42, 28, 14 |
| 7 | 4-(OCH3) | C21H19BrN2O | 395 | 85 | 128-130 | 395[M+], 397[M+2], 363, 317, 287, 210, 142, 105, 77, 41, 14 |
| 8 | 4-CH3 | C21H19BrN2 | 379 | 83 | 148-149 | 379[M+], 381[M+2], 365, 287, 235, 210, 142, 91, 77, 41, 14 |
FW, formula weight; MF, molecular formula; M.p., melting point; m/z, mass-to-change ratio.
IR and NMR spectral data of 1-phenyl-3(5-bromothiophen-2-yl)-5-(substituted phenyl)-2-pyrazolines
| 1 | H | 1,593 | 679 | 562 | 3028-2854 | - | 3.06 | 3.77 | 5.25 | 6.71-7.34 | - | 1 | H | 155.60 | 43.66 | 64.68 | 111.77-146.521 | - |
| | | | | | | | (12 H, m) | | | | | | | | | |||
| 2 | 4-Br | 1,596 | 685 | 5,621 | 3089-2852 | - | 3.07 | 3.82 | 5.26 | 6.70-7.51 | - | 2 | 4-Br | 155.56 | 43.45 | 64.10 | 112.13-144.13 | - |
| | | | | | | | (11 H, m) | | | | | | | | | |||
| 3 | 2-Cl | 1,595 | 690 | 566 | 3065-2852 | - | 3.01 | 3.93 | 5.66 | 6.77-7.48 | - | 3 | 2-Cl | 157.50 | 42.08 | 61.50 | 113.28-143.99 | - |
| | | | | | | | (11 H, m) | | | | | | | | | |||
| 4 | 4-Cl | 1,594 | 688 | 5,31 | 3046-2852 | - | 3.10 | 3.80 | 5.28 | 6.75-7.35 | - | 4 | 4-Cl | 155.82 | 43.70 | 64.75 | 113.52-144.40 | - |
| | | | | | | | (11 H, m) | | | | | | | | | |||
| 5 | 3,4-(OCH3)2 | 1,594 | 678 | 569 | 3073-2873 | 1,254 | 3.08 | 3.76 | 5.17 | 6.75-7.36 | 3.83, 3.87 | 5 | 3,4-(OCH3)2 | 155.63 | 43.81 | 64.89 | 111.68-149.74 | 55.94, 55.98 |
| | | | | | | | (11 H, m) | | | | | | | | | |||
| 6 | 4-I | 1,595 | 680 | 531 | 3090-2852 | - | 3.04 | 3.78 | 5.21 | 6.74-6.69 | - | 6 | 4-I | 156.11 | 43.52 | 64.21 | 93.16-143.45 | - |
| | | | | | | | (11 H, m) | | | | | | | | | |||
| 7 | 4-OCH3 | 1,596 | 670 | 553 | 3095-2852 | 1,249 | 3.07 | 3.77 | 5.24 | 6.75-7.28 | 3.80 | 7 | 4-OCH3 | 155.81 | 43.75 | 64.29 | 113.57-159.13 | 55.28 |
| | | | | | | | (11 H, m) | | | | | | | | | |||
| 8 | 4-CH3 | 1,594 | 680 | 546 | 3095-2854 | - | 3.07 | 3.77 | 5.25 | 6.71-7.34 | 2.31 | 8 | 4-CH3 | 156.10 | 43.72 | 64.47 | 111.68-146.48 | 21.13 |
| (11 H, m) | ||||||||||||||||||
The HOMOCOSY and HSQC data (parts per million) of 1-phenyl-3(5-bromothiophen-2-yl)-5-(phenyl)-2-pyrazoline (1)
| 3.06 | - | Bonded | Bonded | - | 3.06 | Bonded | - | - | ||
| 3.77 | Bonded | - | Bonded | - | 3.77 | Bonded | - | - | ||
| 5.25 | Bonded | Bonded | - | - | 5.25 | - | Bonded | - | ||
| 6.71-7.34 | - | - | - | Bonded | 6.71-7.34 | - | - | Bonded | ||
HOMOCOSY, homonuclear correlation spectroscopy; HSQC, heteronuclear single quantum correlation.
Figure 1HOMOCOSY spectrum of 1-phenyl-3(5-bromothiophen-2-yl)-5-(phenyl)-2-pyrazoline (1).
Figure 2HSQC spectrum of 1-phenyl-3(5-bromothiophen-2-yl)-5-(phenyl)-2-pyrazoline (1).
The antibacterial and antifungal activities of 1-phenyl-3(5-bromothiophen-2-yl)-5-(substitutedphenyl)-2-pyrazolines by disc diffusion method
| 1 | H | 10 | 15 | 20 | 15 | 15 | 1 | 15 | 15 | 15 | 15 |
| 2 | 4-Br | 10 | 15 | 20 | 20 | 17 | 2 | 20 | 20 | 20 | 20 |
| 3 | 2-Cl | 15 | 15 | 15 | 5 | 5 | 3 | 15 | 15 | 15 | 15 |
| 4 | 4-Cl | 3 | 10 | 15 | 15 | 15 | 4 | 15 | 15 | 15 | 15 |
| 5 | 3,4-(OCH3)2 | 17 | 17 | 15 | 17 | 20 | 5 | 17 | 17 | 17 | 17 |
| 6 | 4-I | 15 | 17 | 20 | 17 | 10 | 6 | 17 | 17 | 17 | 17 |
| 7 | 4-OCH3 | 15 | 17 | 20 | 17 | 22 | 7 | 20 | 20 | 20 | 20 |
| 8 | 4-CH3 | 15 | 10 | 15 | 5 | 5 | 8 | 20 | 15 | 15 | 20 |
| Cip | - | 17 | 17 | 20 | 22 | 15 | Ket | 15 | 15 | 15 | 15 |
Cip, ciprofloxacin; Ket, ketoconazole.
Figure 3Antibacterial activities by zone of inhibition of 1-phenyl-3(5-bromothiophen-2-yl)-5-(substituted phenyl)-2-pyrazoline petri dishes (AB1 to AB10).
The antibacterial and antifungal activities of 1-phenyl-3(5-bromothiophen-2-yl)-5-(substituted phenyl)-2-pyrazolines by serial dilution method
| 1 | H | 25 | 50 | 12.5 | 50 | 50 | 1 | 50 | 50 | 50 | 50 |
| 2 | 4-Br | 50 | 25 | 3.13 | 3.13 | 6.25 | 2 | 3.13 | 3.13 | 3.13 | 3.13 |
| 3 | 2-Cl | 25 | 25 | 25 | 100 | 100 | 3 | 25 | 25 | 25 | 25 |
| 4 | 4-Cl | 200 | 50 | 25 | 25 | 25 | 4 | 25 | 25 | 25 | 3.13 |
| 5 | 3,4-(OCH3)2 | 6.25 | 6.25 | 12.5 | 6.25 | 3.13 | 5 | 6.25 | 6.25 | 6.25 | 6.25 |
| 6 | 4-I | 25 | 6.25 | 3.13 | 6.25 | 50 | 6 | 6.25 | 6.25 | 6.25 | 6.25 |
| 7 | 4-OCH3 | 12.5 | 6.25 | 3.13 | 6.25 | 1.5 | 7 | 3.13 | 3.13 | 3.13 | 3.13 |
| 8 | 4-CH3 | 50 | 100 | 50 | 200 | 200 | 8 | 50 | 50 | 50 | 50 |
| Cip | - | 6.25 | 6.25 | 3.13 | 1.5 | 12.5 | Ket | 12.5 | 12.5 | 12.5 | 12.5 |
Cip, ciprofloxacin; Ket, ketoconazole.
Figure 4Antifungal activities of spectrum of 1-phenyl-3(5-bromothiophen-2-yl)-5-(substituted phenyl)-2-pyrazoline pretri dishes (AF1 to AF8).
Figure 5Comparison of potency of pyrazolines with ciprofloxacin (standard) against bacterial strains from serial dilution method.
Figure 6Comparison of potency of pyrazolines with ciprofloxacin (standard) against fungal strains from serial dilution method.
Figure 7SEM images of pure fly ash and fly ash:H2SO4. (a) Pure fly ash (1 μm), (b) pure fly ash (50 μm), (c) fly ash:H2SO4 (1 μm) (red bold arrow, corroded), and (d) fly ash:H2SO4 (50 μm) (red bold arrow, corroded).
Scheme 1Synthesis of 1-phenyl-3(5-bromothiophen-2-yl)-5-(substituted phenyl)-2-pyrazolines.